Ftse Mib
34.305,75
-0,20%
DAX
18.522,08
-0,42%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
63.526,64
-2,04%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

PCSA

Processa Pharmaceuticals (PCSA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
13/10/202319:08GlobeNewswire Inc.Processa Pharmaceuticals to Present at the ThinkEquity ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/10/202300:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/09/202322:09Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/09/202323:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCSAProcessa Pharmaceuticals Inc
06/09/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
17/08/202314:05GlobeNewswire Inc.Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer CareNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/08/202322:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
10/08/202322:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
09/08/202322:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
08/08/202314:15GlobeNewswire Inc.Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive OfficerNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/06/202322:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
14/06/202322:15GlobeNewswire Inc.Next Generation Chemotherapy: Improved Treatment for More PatientsNASDAQ:PCSAProcessa Pharmaceuticals Inc
12/06/202322:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PCSAProcessa Pharmaceuticals Inc
22/05/202314:05GlobeNewswire Inc.Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug CongressNASDAQ:PCSAProcessa Pharmaceuticals Inc
18/05/202314:00GlobeNewswire Inc.Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology InitiativeNASDAQ:PCSAProcessa Pharmaceuticals Inc
15/05/202316:03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PCSAProcessa Pharmaceuticals Inc
01/05/202316:03Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PCSAProcessa Pharmaceuticals Inc
01/05/202316:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
01/05/202316:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
28/04/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual MeetingNASDAQ:PCSAProcessa Pharmaceuticals Inc
14/04/202322:31Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202322:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202322:01GlobeNewswire Inc.Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial ResultsNASDAQ:PCSAProcessa Pharmaceuticals Inc
23/03/202313:30GlobeNewswire Inc.Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
17/03/202313:30GlobeNewswire Inc.Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
07/03/202314:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/02/202314:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Prioritization on Development of Next Generation ChemotherapiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
15/02/202314:30GlobeNewswire Inc.Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq RulesNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
FBK
Finecobank
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
ENI
Eni
BIT
BC
Brunello Cucinelli
BIT
PRY
Prysmian
BIT
G
Generali
BIT
SPM
Saipem
BIT
LDO
Leonardo
BIT
MONC
Moncler
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network